The effect of mammographic screening and hormone replacement therapy use on breast cancer incidence in England and Wales

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 11, 2007, Pages 2257-2261

  Waller, Michael ^a   Moss, Sue ^a   Watson, Joanna ^b   Møller, Henrik ^c  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LIFESPAN; MAMMOGRAPHY; PRIORITY JOURNAL; UNITED KINGDOM;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; ENGLAND; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; POSTMENOPAUSE; SENSITIVITY AND SPECIFICITY; WALES;

EID: 38849193950     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0262     Document Type: Article

References (20)

1. Advisory Committee on Breast Cancer Screening. Screening for breast cancer in England: past and future. NHSBSP Publication No. 61. 2006.
2. Moss S. A trial to study the effect on breast cancer mortality of annual mammographic screening in women starting at age 40. Trial Steering Group. J Med Screen 1999;6:144-8.
3. Quinn M, Allen E, on behalf of the United Kingdom Association of Cancer Registries. Changes in incidence of and mortality from breast cancer in England and Wales since introduction of screening. BMJ 1995;311:1391-5.
4. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol 2005;34:405-12.
5. Moller B, Fekjaer H, Hakulinen T, et al. The influence of mammographic screening on national trends in breast cancer incidence. Eur J Cancer Prev 2005;14:117-28.
6. Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 2004;328:921-4.
7. International Agency for Research on Cancer. Breast cancer screening. IARC Handbooks of Cancer Prevention 2002;7:1-248.
8. Moss S, Blanks R. Calculating appropriate target cancer detection rates and expected interval cancer rates for the UK NHS Breast Screening Programme. Interval Cancer Working Group. J Epidemiol Community Health 1998;52:111-5.
9. Blanks RG, Moss SM, Patnick J. Results from the UK NHS breast screening programme 1994-1999. J Med Screening 2000;7:195-8.
10. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 2004;6:229-39.
11. Ursin G, Bernstein L, Pike MC. Breast cancer. Cancer Surv 1994;19-20:241-64.
12. Beral V, Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
13. Tjonneland A, Christensen J, Thomsen BL, et al. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer 2004;100:2328-37.
14. Clayton D, Schifflers E. Models for temporal variation in cancer rates. I: Age-period and age-cohort models. Stat Med 1987a;6:449-67.
15. Clayton D, Schifflers E. Models for temporal variation in cancer rates. II: Age-period-cohort models. Stat Med 1987;6:469-81.
16. Olsen AH, Jensen A, Njor SH, et al. Breast cancer incidence after the start of mammography screening in Denmark. Br J Cancer 2003;88:362-5.
17. McCann J, Treasure P, Duffy S. Modelling the impact of detecting and treating ductal carcinoma in situ in a breast screening programme. J Med Screen 2004;11:117-25.
18. Banks E, Reeves G, Beral V, et al. Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study. BMJ 2004;329:477.
19. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of oestrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
20. Watson J, Wise L, Green J. Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol 2007;63:843-9.